Marksans Pharma Limited (NSE:MARKSANS)

Marksans Pharma Statistics

Total Valuation

Marksans Pharma has a market cap or net worth of INR 83.08 billion. The enterprise value is 79.47 billion.

Market Cap	83.08B
Enterprise Value	79.47B

Important Dates

The next estimated earnings date is Thursday, November 13, 2025.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	Aug 1, 2025

Share Statistics

Marksans Pharma has 453.16 million shares outstanding. The number of shares has decreased by -0.27% in one year.

Current Share Class	453.16M
Shares Outstanding	453.16M
Shares Change (YoY)	-0.27%
Shares Change (QoQ)	-0.15%
Owned by Insiders (%)	43.87%
Owned by Institutions (%)	14.33%
Float	214.46M

Valuation Ratios

The trailing PE ratio is 23.69 and the forward PE ratio is 18.98.

PE Ratio	23.69
Forward PE	18.98
PS Ratio	3.13
PB Ratio	3.34
P/TBV Ratio	3.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	22.70
EV / Sales	3.00
EV / EBITDA	15.93
EV / EBIT	19.18
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.13
Debt / EBITDA	0.65
Debt / FCF	n/a
Interest Coverage	27.99

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	10.07%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	14.41M
Profits Per Employee	1.90M
Employee Count	1,840
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Marksans Pharma has paid 1.09 billion in taxes.

Income Tax	1.09B
Effective Tax Rate	23.62%

Stock Price Statistics

The stock price has decreased by -30.45% in the last 52 weeks. The beta is 1.17, so Marksans Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.17
52-Week Price Change	-30.45%
50-Day Moving Average	174.20
200-Day Moving Average	220.52
Relative Strength Index (RSI)	59.66
Average Volume (20 Days)	1,296,286

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Marksans Pharma had revenue of INR 26.52 billion and earned 3.50 billion in profits. Earnings per share was 7.74.

Revenue	26.52B
Gross Profit	14.54B
Operating Income	4.14B
Pretax Income	4.61B
Net Income	3.50B
EBITDA	4.72B
EBIT	4.14B
Earnings Per Share (EPS)	7.74

Balance Sheet

The company has 7.06 billion in cash and 3.22 billion in debt, giving a net cash position of 3.84 billion or 8.48 per share.

Cash & Cash Equivalents	7.06B
Total Debt	3.22B
Net Cash	3.84B
Net Cash Per Share	8.48
Equity (Book Value)	24.89B
Book Value Per Share	54.44
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 54.82%, with operating and profit margins of 15.62% and 13.20%.

Gross Margin	54.82%
Operating Margin	15.62%
Pretax Margin	17.36%
Profit Margin	13.20%
EBITDA Margin	17.80%
EBIT Margin	15.62%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 0.44%.

Dividend Per Share	0.80
Dividend Yield	0.44%
Dividend Growth (YoY)	33.33%
Years of Dividend Growth	2
Payout Ratio	n/a
Buyback Yield	0.27%
Shareholder Yield	0.72%
Earnings Yield	4.21%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.

Last Split Date	Mar 11, 2008
Split Type	Forward
Split Ratio	10

Scores

Altman Z-Score	n/a
Piotroski F-Score	2